IP Library Granted Patent US 8,983,595
Granted Patent B2
US 8,983,595 · App. 14/086,607 · Granted Mar 17, 2015

Renal neuromodulation for treatment of patients with chronic heart failure

Inventors: Howard R. Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
A61B18/1492A61M5/14276A61M5/1723A61M2210/1082A61N1/0551A61N1/326A61N1/36007A61N1/36114A61N1/36117A61M1/3627A61M5/142A61N1/05A61N5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,983,595
App. No.
14/086,607
Granted
Mar 17, 2015
Kind
B2
Abstract

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

Claims (29)

1. A method, comprising:

positioning a catheter having a therapeutic element within a renal blood vessel of a human patient diagnosed with chronic heart failure; and

reducing neural traffic to and/or from a kidney of the patient via the therapeutic element,

wherein reducing the neural traffic to and/or from the kidney results in a therapeutically beneficial reduction in clinical symptoms of chronic heart failure in the patient.

2. The method of claim 1 wherein positioning a catheter having a therapeutic element within a renal blood vessel comprises intravascularly positioning a catheter comprising one or more electrodes within a renal artery of the patient.

3. The method of claim 2 wherein intravascularly positioning the catheter comprising one or more electrodes within the renal artery comprises placing the one or more electrodes in apposition with an inner wall of the renal artery.

4. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises blocking neural traffic to and/or from the kidney.

5. The method of claim 1 wherein reducing neural traffic to and/or from a kidney comprises delivering electrical energy via the therapeutic element to renal nerves proximate to the renal blood vessel.

6. The method of claim 5 wherein delivering electrical energy via the therapeutic element comprises delivering radiofrequency (RF) energy via the therapeutic element to the renal nerves.

7. The method of claim 5 wherein delivering electrical energy via the therapeutic element comprises ablating at least a portion of the renal nerves.

8. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises ablating a renal nerve of the patient.

9. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises partially ablating a renal nerve of the patient.

10. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises denervating the kidney of the patient.

11. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises modulating sympathetic nerves that innervate the kidney of the patient.

12. The method of claim 1 wherein positioning a catheter having a therapeutic element within a renal blood vessel of a human patient comprises positioning the catheter via a guide catheter.

13. The method of claim 1 wherein positioning a catheter having a therapeutic element within a renal blood vessel of a human patient comprises intravascularly positioning the catheter via a guide wire.

14. The method of claim 1 wherein positioning a catheter having a therapeutic element within a renal blood vessel of a human patient comprises positioning a drug delivery device within a renal artery of the patient.

15. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient via the therapeutic element comprises at least partially ablating renal nerves of the patient via delivery of chemical agents to the renal nerves.

16. The method of claim 1 wherein positioning a catheter having a therapeutic element within a renal blood vessel of a human patient comprises positioning a bipolar electrode pair within a renal artery of the patient.

17. The method of claim 16 wherein reducing neural traffic to and/or from a kidney comprises delivering electrical energy via the bipolar electrode pair to renal nerves proximate the renal artery.

18. A method of treating a patient diagnosed with chronic heart failure, the method comprising:

percutaneously delivering a renal denervation catheter through an abdominal aorta of a human patient to a renal blood vessel of the patient and proximate to neural fibers that innervate a kidney of the patient; and

at least partially ablating the neural fibers via the catheter,

wherein at least partially ablating the neural fibers results in a therapeutically beneficial reduction in clinical symptoms of heart failure in the patient.

19. The method of claim 18 wherein at least partially ablating the neural fibers comprises reducing afferent neural signals along the neural fibers.

20. The method of claim 18 wherein at least partially ablating the neural fibers comprises reducing efferent neural signals along the neural fibers.

21. The method of claim 18 , further comprising removing the renal denervation catheter from the patient after therapy.

22. The method of claim 18 , further comprising monitoring a parameter of the catheter and/or a physiological parameter of the patient before and during ablation of the neural fibers.

23. The method of claim 22 wherein at least partially ablating the neural fibers via the catheter comprises delivering energy to the neural fibers via the catheter to at least partially ablate the neural fibers, and wherein the method further comprises regulating energy delivery based, at least in part, on the monitored parameter.

Continuity (9)
Continuation 13861178 · Apr 11, 2013
Continuation 13361019 · Jan 30, 2012
Continuation 11688178 · Mar 19, 2007
Continuation 11144173 · Jun 3, 2005
Continuation 10408665 · Apr 8, 2003
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Related Publication 20140088561A1 · Mar 27, 2014